ArticleRevista peruana de medicina experimental y salud publica2025
Characteristics of covid-19 in miners and former miners with a history of silicosis.
Article in Revista peruana de medicina experimental y salud publica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prevalence of chronic respiratory disease symptoms and associated occupational risk factors among certified silicosis patients of Rajasthan.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the SARS-CoV-2 pandemic, it was suggested that individuals with chronic lung diseases, such as silicosis, could be at increased risk of complications; however, the evidence remains limited. This study describes the prevalence of COVID-19 among 51 miners and former miners with silicosis who were part of an occupational surveillance program. 96% were over 60 years old, 37.2% had moderate or severe silicosis, and 67% had at least one comorbidity. The prevalence of COVID-19 was 15.7%, lower than the general population, with mild cases and no reported deaths. 94.1% had received at least two doses of vaccine; of these, 12.5% were affected by COVID-19, compared to 66.7% of those who were not vaccinated. These findings suggest that vaccination and preventive measures may have contributed to reduce transmission and severity, highlighting the importance of maintaining protection for individuals with chronic respiratory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.